Drug
Forodesine hydrochloride clinical trials
A product of Forodesine; its studies count on that page too.
- studies test it
- 10
- open now
- 0
- in phase 3
- 0
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2004 (3)
| Year | Studies |
|---|---|
| 2003 | 2 |
| 2004 | 3 |
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 6
- Phase 2
- 7
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 0
Studies
Open first, then newest update. How each study uses forodesine hydrochloride is read from its arms, and is right about nine times in ten.
Testing it · 10
- Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma PatientsCompletedPhase 1/2Mundipharma K.K.NCT01776411Written as forodesine hydrochloride
- Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell MalignanciesCompletedPhase 1Mundipharma K.K.NCT00823355Written as forodesine hydrochloride
- Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell LymphomaCompletedPhase 1BioCryst PharmaceuticalsNCT00098332Written as forodesine hydrochloride
- BCX-1777 in Treating Patients With Refractory CancerCompletedPhase 1BioCryst PharmaceuticalsNCT00073944Written as forodesine hydrochloride
- BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell LymphomaCompletedPhase 1/2BioCryst PharmaceuticalsNCT00061880Written as forodesine hydrochloride
- Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2BioCryst PharmaceuticalsNCT00289549Written as forodesine hydrochloride (BCX-1777)
- Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)CompletedPhase 2BioCryst PharmaceuticalsNCT00640523Written as forodesine HCl
- Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment RegimensTerminatedPhase 2BioCryst PharmaceuticalsNCT00419081Written as Forodesine Hydrochloride Capsules (100 mg)
- Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic LeukemiaCompletedPhase 1/2BioCryst PharmaceuticalsNCT00289562Written as forodesine hydrochloride (BCX-1777)
- Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell LeukemiaCompletedPhase 2BioCryst PharmaceuticalsNCT00095381Written as forodesine hydrochloride (BCX-1777)
Codes
What other systems call forodesine hydrochloride · ClinicalTrials.gg INT015321
- Wikidata Q27265452forodesine hydrochlorideOne source Wikidata
- NCI Thesaurus C26655Forodesine HydrochlorideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27265452 | forodesine hydrochloride | One source Wikidata |
| NCI Thesaurus | C26655 | Forodesine Hydrochloride | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.